Bristol Opdivo for skin cancer to get US, EU review

 The applications are based on results from the Phase 3 CheckMate -76K trial, in which Opdivo demonstrated a statistically significant and clinically meaningful benefit in recurrence-free survival

The U.S. Food and Drug Administration has assigned a target action date of October 13, 2023

U.S. Food and Drug Administration Accepts Bristol Myers Squibb’s Supplemental Biologics License Application and European Medicines Agency Validates Application for Opdivo (nivolumab) as an Adjuvant Treatment for Patients with Completely Resected Stage IIB or IIC Melanoma

https://finance.yahoo.com/news/u-food-drug-administration-accepts-115900042.html